PROF. MARK J. COOK (Orcid ID : 0000-0002-8875-4135)

Article type : Commentary

‘Truths and roses have thorns about them’

- Henry David Thoreau

Mark J. Cook

Departments of Medicine and Engineering,

University of Melbourne

Victoria, Australia

Phone +61 3 9231 2240, Fax +61 3 9231 2250, email markcook@unimelb.edu.au

The ROSE study, reported in this edition of the journal, provides new information regarding the use of stereotactic radiosurgery (SRS) for the treatment of refractory mesial temporal lobe epilepsy. SRS holds significant appeal as a non-invasive means of treatment for epilepsy, though there have been no randomised controlled clinical trials to establish this. Success in treating vascular malformations¹ generated hope that epilepsy caused by focal pathologies such as hippocampal sclerosis could be treated effectively also. Animal studies appeared encouraging². Application to cavernous malformations proved disappointing³, but a role was established in managing epilepsy related to hypothalamic hamartomas^{4,5}. Early studies in focal epilepsies did not seem promising⁶, and though later work was more encouraging⁷, the variability in pathologies, dose, and target volumes complicated interpretation however. Other important features of SRS include that there is significant delay before the benefits are realised, with seizure improvement delayed for months or years after the procedure.

Presumably this relates to delayed effects of the radiotherapy on non-neuronal tissues, particularly vascular structures. The randomised, single-blinded controlled international study **This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/epi.14433**

This article is protected by copyright. All rights reserved

reported here was performed over multiple centres but ultimately was significantly limited by lower than anticipated recruitment, markedly reducing the power of analysis permitted. They found that standard anterior temporal lobectomy (ATL) resulted in a higher number of seizure-free outcomes than SRS, though the difference was not clinically significant given the relatively small numbers. Conversely significant verbal memory disturbances were more common than the ATL patients, though again the difference did not reach statistical significance. The number of adverse events is noteworthy – 12 (5 serious) in the SRS group, and 5 (2 serious) in the ATL group. Nearly two-thirds of the SRS group required steroid therapy, and visual field defects were almost as frequent as in the ATL group. McGonigal and colleagues recently published a practice guideline for radiosurgery for epilepsy⁸, indicating that level 2 evidence supported SRS as an efficacious treatment for mesial temporal lobe epilepsy, possible with superior neuropsychological outcomes. However a recent systematic review⁹ reports a similar level of success as the ROSE study from 170 patients included in 16 eligible studies (58% on average, ranging from 25-95%), and also points out that a total of 20% of subjects required subsequent surgery for complications such as radionecrosis and cyst formation. Overall, whilst it is clear that SRS may represent an alternative to surgical therapy for those subjects who are unwilling or unable to undertake a standard ATL, there are strong indicators that this procedure is inferior to standard approaches and has limited benefits in terms of avoiding adverse events and neuropsychological impairment. As alternatives such as MR focussed ultrasound and laser interstitial thermal therapy evolve and become more widely available, the role of SRS is likely to become less relevant, particularly given the attendant morbidities.

I confirm that I have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

I have no conflicts of interest to report.

References:

1. Steiner L, Lindquist C, Adler JR, et al. Clinical outcome of radiosurgery for cerebral arteriovenous malformations. *J Neurosurg* 1992;77:1–8.
2. Sun B, DeSalles AA, Medin PM, et al. Reduction of hippocampal-kindled seizure activity in rats by stereotactic radiosurgery. *Exp Neurol* 1998;154:691–5.
3. Shih Y-H, Pan DH-C. Management of supratentorial cavernous malformations: craniotomy versus gammaknife radiosurgery. *Clinical neurology and neurosurgery* 2005;107:108–12.
4. Mathieu D, Kondziolka D, Niranjan A, et al. Gamma knife radiosurgery for refractory epilepsy caused by hypothalamic hamartomas. *Stereotact Funct Neurosurg* 2006;84:82–7.
5. Régis J, Lagmari M, Carron R, et al. Safety and efficacy of Gamma Knife radiosurgery in hypothalamic hamartomas with severe epilepsies: A prospective trial in 48 patients and review of the literature. *Epilepsia* 2017;58 Suppl 2:60–71.
6. Barcia JA, Barcia-Salorio JL, López-Gómez L, et al. Stereotactic radiosurgery may be effective in the treatment of idiopathic epilepsy: report on the methods and results in a series of eleven cases. *Stereotact Funct Neurosurg* 1994;63:271–9.
7. Régis J, Peragui JC, Rey M, et al. First selective amygdalohippocampal radiosurgery for 'mesial temporal lobe epilepsy'. *Stereotact Funct Neurosurg* 1995;64 Suppl 1:193–201.
8. McGonigal A, Sahgal A, De Salles A, et al. Radiosurgery for epilepsy: Systematic review and International Stereotactic Radiosurgery Society (ISRS) practice guideline. *Epilepsy Res* 2017;137:123–31.
9. Eekers DBP, Pijnappel EN, Schijns OEMG, et al. Evidence on the efficacy of primary radiosurgery or stereotactic radiotherapy for drug-resistant non-neoplastic focal epilepsy in adults: A systematic review. *Seizure* 2018;55:83–92.

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Cook, MJ

Title:

"Truths and roses have thorns about them" - Henry David Thoreau

Date:

2018-06-01

Citation:

Cook, M. J. (2018). "Truths and roses have thorns about them" - Henry David Thoreau. *EPILEPSIA*, 59 (6), pp.1208-1209. <https://doi.org/10.1111/epi.14433>.

Persistent Link:

<http://hdl.handle.net/11343/284037>